Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Original Article
T. Facon, S. Kumar, T. Plesner, R.Z. Orlowski, P. Moreau, N. Bahlis, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C.P. Venner, K. Weisel, J.R. Mace, N. Raje, M. Attal, M. Tiab, M. Macro, L. Frenzel, X. Leleu, T. Ahmadi, C. Chiu, J. Wang, R.V. Rampelbergh, C.M. Uhlar, R. Kobos, M. Qi, and S.Z. Usmani
N Engl J Med 2019;380:2104-2115
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Sunday, May 30, 2021 - 11:59pm.